Study:
A Phase I Trial of Intravenous Paclitaxel, Intraperitoneal Carboplatin and Intraperitoneal Paclitaxel or Intravenous Docetaxel, Intraperitoneal Carboplatin and Intraperitoneal Paclitaxel or Intravenous Paclitaxel, Intraperitoneal Carboplatin, Intraperitoneal Paclitaxel and CTEP-Supplied Agent Bevacizumab (NSC 704865, IND 7921) in Patients With Previously Untreated Ovarian, Fallopian Tube or Primary Peritoneal Carcinoma
Rationale:
Drugs used in chemotherapy, such as carboplatin, docetaxel, and paclitaxel, work
in different ways to stop tumor cells from dividing so they stop growing or die. Combining
more than one drug and giving them in different ways may kill more tumor cells.
Purpose:
This phase I trial is studying the side effects and best dose of intraperitoneal infusions
of carboplatin when given together with intravenous infusions of either docetaxel or
paclitaxel followed by intraperitoneal paclitaxel in treating patients with stage II, stage
III, or stage IV ovarian epithelial, fallopian tube, or primary peritoneal cavity carcinoma
(cancer). Drugs used in chemotherapy, such as carboplatin, docetaxel, and paclitaxel, work
in different ways to stop tumor cells from dividing so they stop growing or die. Combining
more than one drug and giving them in different ways may kill more tumor cells
Study Status: Completed
Recruiting:
n/a
| Condition |
Intervention |
Phase |
Brenner Tumor
Fallopian Tube Cancer
Ovarian Carcinosarcoma
Ovarian Clear Cell Cystadenocarcinoma
Ovarian Endometrioid Adenocarcinoma
Ovarian Mixed Epithelial Carcinoma
Ovarian Mucinous Cystadenocarcinoma
Ovarian Serous Cystadenocarcinoma
Ovarian Undifferentiated Adenocarcinoma
Primary Peritoneal Cavity Cancer
Stage II Ovarian Epithelial Cancer
Stage III Ovarian Epithelial Cancer
Stage IV Ovarian Epithelial Cancer |
Drug: carboplatin
Drug: paclitaxel
Drug: docetaxel
Biological: bevacizumab |
Phase 1 |
Verified by
National Cancer Institute (NCI)
March, 2013
Sponsored by: National Cancer Institute (NCI)
Information provided by: National Cancer Institute (NCI)
ClinicalTrials.gov identifier: NCT00085358
Study Type: Interventional
Study Design: Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
Cleveland Clinic Cancer Center/Fairview Hospital
Cleveland, Ohio 44111
United States
Joan Walker., Principal Investigator